Valuation : Prothena Corporation plc

Market Cap 493M 426M 400M 365M 686M 46.82B 690M 4.73B 1.84B 23.82B 1.85B 1.81B 78.97B P/E 2026 *
87.4x
P/E 2027 * -10.3x
Enterprise Value 493M 426M 400M 365M 686M 46.82B 690M 4.73B 1.84B 23.82B 1.85B 1.81B 78.97B EV / Sales 2026 *
5.93x
EV / Sales 2027 * 20.2x
Free-Float
78.36%
Yield 2026 *
-
Yield 2027 * -
1 day-1.93%
1 week+1.41%
Current month+0.32%
1 month+12.61%
3 months+2.07%
6 months-0.21%
Current year-1.78%
1 week 8.95
Extreme 8.95
9.75
1 month 8.04
Extreme 8.04
9.82
Current year 7.73
Extreme 7.73
11.8
1 year 7.73
Extreme 7.73
11.8
3 years 4.32
Extreme 4.32
56.04
5 years 4.32
Extreme 4.32
79.75
10 years 4.32
Extreme 4.32
79.75
Manager TitleAgeSince
Chief Executive Officer 57 29/09/2016
Director of Finance/CFO 52 31/03/2013
Chief Operating Officer 52 28/09/2021
Director TitleAgeSince
Chairman 76 19/12/2012
Director/Board Member 72 19/12/2012
Director/Board Member 63 19/12/2012
Date Insider Type Main position Quantity % Market Cap. Importance
20/08/26 Buy 50,000 0.0955%
18/08/26 Don -627,553 1.1987%
10/08/26 Don 251,553 0.4805%
Change 5-day change 1-year change 3-year change Capi.($)
-1.93%+1.41%+13.42%-82.75% 493M
-0.25%-4.10%+38.38%+92.61% 68.21B
+2.08%+0.65%+49.08%+90.23% 64.25B
+1.78%-1.05%-15.29%+366.78% 26.54B
+0.90%-7.79%+3.15%-14.93% 25.61B
+1.30%+0.97%+31.96%-18.14% 19.88B
-0.38%-12.42%+224.86%+373.18% 17.13B
+0.65%-5.83%+1.44%+544.44% 14.93B
+0.14%+1.30%+52.85%+155.19% 14.1B
-0.01%-0.22%+23.29%+191.43% 12.45B
Average +0.40%-3.23%+42.31%+169.80% 26.36B
Weighted average by Cap. +0.78%-3.15%+41.72%+152.35%

Financials

2026 *2027 *
Net sales 83.16M 71.73M 67.47M 61.47M 116M 7.89B 116M 798M 310M 4.01B 312M 305M 13.31B 24.38M 21.03M 19.78M 18.02M 33.88M 2.31B 34.07M 234M 91.01M 1.18B 91.52M 89.53M 3.9B
Net income 6.22M 5.37M 5.05M 4.6M 8.65M 591M 8.7M 59.7M 23.24M 300M 23.37M 22.86M 996M -49.57M -42.76M -40.23M -36.65M -68.91M -4.7B -69.29M -476M -185M -2.39B -186M -182M -7.94B
Net Debt - -
Logo Prothena Corporation plc
Prothena Corporation plc is an Ireland-based late-stage clinical biotechnology company. The Company is engaged in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid diseases. The Company is advancing a pipeline of therapeutic candidates for a range of indications and targets to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins. The Company’s pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases, including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a range of other neurodegenerative diseases. Its clinical programs include birtamimab for the potential treatment of AL amyloidosis, prasinezumab for the potential treatment of Parkinson’s disease, NNC6019/PRX004 for the potential treatment of ATTR amyloidosis, and PRX005 and PRX012 for the potential treatment of Alzheimer’s disease.
Employees
67
Date Price Change Volume
02/09/26 US$9.380 -2.39% 59,629
01/09/26 US$9.610 +2.78% 267,669
31/08/26 US$9.350 +0.21% 335,149
28/08/26 US$9.330 +2.64% 498,115
27/08/26 US$9.090 -1.73% 338,921
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
9.610USD
Average target price
21.40USD
Spread / Average Target
+122.68%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PRTA Stock